Tenapanor: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tenapanor. Educational only — not medical advice.
Labeled uses
XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Source: FDA labeling via NIH DailyMed (set c57e279c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.